Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.

BACKGROUND: The aim of this study was to detect the epidermal growth factor receptor (EGFR)-activating mutations and other oncogene alterations in patients with non-small-cell lung cancers (NSCLC) who experienced a treatment failure in response to EGFR-tyrosine kinase inhibitors (TKIs) with a next generation sequencer.
METHODS: Fifteen patients with advanced NSCLC previously treated with EGFR-TKIs were examined between August 2005 and October 2014. For each case, new biopsies were performed, followed by DNA sequencing on an Ion Torrent Personal Genome Machine (PGM) system using the Ion AmpliSeq Cancer Hotspot Panel version 2.
RESULTS: All 15 patients were diagnosed with NSCLC harboring EGFR-activating mutations (seven cases of exon 19 deletion, seven cases of L858R in exon 21, and one case of L861Q in exon 21). Of the 15 cases, acquired T790M resistance mutations were detected in 9 (60.0%) patients. In addition, other mutations were identified outside of EGFR, including 13 cases (86.7%) exhibiting TP53 P72R mutations, 5 cases (33.3%) of KDR Q472H, and 2 cases (13.3%) of KIT M541L.
CONCLUSIONS: Here, we showed that next-generation sequencing (NGS) is able to detect EGFR T790M mutations in cases not readily diagnosed by other conventional methods. Significant differences in the degree of EGFR T790M and other EGFR-activating mutations may be indicative of the heterogeneity of disease phenotype evident within these patients. The co-existence of known oncogenic mutations within each of these patients may play a role in acquired EGFR-TKIs resistance, suggesting the need for alternative treatment strategies, with PCR-based NGS playing an important role in disease diagnosis.

Background

Recent advances in biomedical research have provided a greater understanding of the molecular basis of disease, with significant implications for therapeutic intervention. Somatic mutations, such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements, play a significant role in the pathogenesis of non-small-cell lung cancer (NSCLC), with treatment decisions often based upon the outcome of these genetic tests [1-5].

Both EGFR and ALK function as a receptor tyrosine kinase, which are readily inhibited by a series of tyrosine kinase inhibitors (TKI), including gefitinib [6], erlotinib [7], and crizotinib [2]. Despite the initial treatment efficacy of these TKIs for the treatment of NSCLC, acquired resistance was found to develop in almost all cases. The well-known mechanism of acquired EGFR-TKIs resistance include second site mutations within the EGFR kinase domain [8, 9], up-regulation of alternative signaling pathways, such as MET [10], histologic transformation, epithelial to mesenchymal transition, and small cell transformation [11]. Although many resistance mechanisms have been clarified, the EGFR kinase domain mutation T790M in exon 20 accounts for nearly half of all acquired resistance, making testing for this mutation a key factor in determining following treatment strategies in the era of second- and third-generation EGFR-TKIs [12, 13].

The recent development of next-generation sequencing (NGS) as a diagnostic tool in the clinical setting has enabled us to determine rapid, targeted sequencing of tumors for causative mutations. When combined with various selective capture approaches, NGS has allowed for the efficient simultaneous genetic analysis of a large number of candidate genes. Here, we applied a polymerase chain reaction (PCR) based NGS in determining oncogene alternations in the state of disease progression.

PCR based next-generation sequencing is an outstanding tool to provide a comprehensive genomic diagnosis in patients with recurrent NSCLC [14]. The primary aim of this study was to evaluate EFGR T790M secondary mutations, along with other oncogenic alterations, in NSCLC patients previously diagnosed with EGFR activating mutations who experienced disease recurrence after treatment with first-generation EGFR-TKIs.

Methods

Patients and treatment regimens

Fifteen patients with NSCLC previously treated with EGFR-TKIs were examined between August 2005 and October 2014 at the Institute of Biomedical Research and Innovation in Kobe City, Japan. Patients were treated with either of erlotinib or gefitinib daily, at initial daily doses of 150 (erlotinib) and 250 (gefitinib) mg/day. Standard Response Evaluation Criteria in Solid Tumors (RECIST 1.0) was used to evaluate treatment response. Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. We obtained written informed consents from all the participants. This study was approved by the Research Ethics Committee of the Institute of Biomedical Research and Innovation.

EGFR mutational analysis

A quantity of cancer cells sufficient for a pathologic diagnosis (i.e., several hundred cells) were obtained from formalin-fixed paraffin-embedded (FFPE) biopsy specimens by manual micro-dissection. Similar biopsy specimens were used to analyze EGFR somatic mutations in exons 18–21 [15, 16].

MET gene amplification

For each patient, DNA was extracted, and the concentration measured using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Rockland, DE). MET copy number gains (CNG) analysis was performed using the One-Step Real Time PCR System (Thermo Fisher Scientific, Foster City, CA) under the following conditions: one cycle of 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The qPCR reaction mixture contained 10 μL of 2X TaqMan genotyping master mix, 1 μL of the TaqMan copy number target assay, 1 μL of the TaqMan copy number reference assay (RNase P, which is known to exist only in two copies in a diploid genome), 4 μL of nuclease-free water, and 4 μL of DNA (diluted to a concentration of 5 ng/μL). Each sample was run in a minimum of four replicates. Amplification results were then analyzed using the CopyCaller Software (Thermo Fisher Scientific) for post-PCR data analysis. To accurately detect MET CNG, we analyzed the previous reported region of MET [17], a region spanning the intron 20–exon 21 boundary (TaqMan copy number assay Hs02884964_cn).

Ion torrent PGM library preparation and sequencing

An Ion Torrent adapter-ligated library was generated using an Ion AmpliSeq Library Kit 2.0 according to the manufacturer’s protocol (Thermo Fisher Scientific, Rev. 5; MAN0006735). Briefly, 50 ng of pooled amplicons and the Ion AmpliSeq Cancer Hotspot Panel version 2 (Thermo Fisher Scientific) were end-repaired, and Ion Torrent adapters P1 and A were ligated using DNA ligase. Following AMPure bead (Beckman Coulter, Brea, CA, USA) purification, the concentration and size of the library were determined using the Life Technologies StepOne system (Thermo Fisher Scientific) and Ion Library TaqMan quantitation assay kit (Thermo Fisher Scientific). Sample emulsion PCR, emulsion breaking, and enrichment were performed using the Ion PGM IC 200 Kit (Thermo Fisher Scientific), according to the manufacturer’s instructions. Briefly, an input concentration of one DNA template copy/Ion Sphere Particle (ISP) was added to the emulsion PCR master mix, and the emulsion was generated using the Ion Chef (Thermo Fisher Scientific). Next, ISPs were recovered and template-positive ISPs enriched using Dynabeads MyOne Streptavidin C1 beads (Thermo Fisher Scientific). Sequencing was undertaken using 314 BC chips on the Ion Torrent PGM for 65 cycles using barcoded samples. The totally turnaround time from library preparation to the end of sequencing is about 2 days.

Variant calling

After sequencing, data were processed using the Ion Torrent platform-specific pipeline software Torrent Suite to generate sequence reads, trim adapter sequences, and remove poor signal-profile reads. Initial variant calling was generated using Torrent Suite Software v4.0 using the variant caller plug-in. To eliminate erroneous base calling, three filtering steps were used. The first filter was set at an average total coverage depth of >100, variant coverage of >20, and P values <0.01. The second filter was employed by visually examining mutations using the Integrative Genomics Viewer (http//www.broadinstitute.org/igv) or CLC Genomics Workbench version 7.04 (Qiagen) software. Finally, possible strand-specific errors, such as mutation only detected in only the plus or minus strand were removed.

Results

A summary of patient characteristics can be found in Table 1. All patients were Japanese, consisting of 10 females (76.7 %) and 5 males (33.3 %). Nine patients (60.0 %) were never smokers, and the remaining six patients (40.0 %) were former smokers. All patients had stage IV adenocarcinoma, as defined based upon TNM classification criteria (7th edition) [18]. Eight patients received erlotinib, and four patients were treated with gefitinib. The remaining patient was treated first with gefitinib, then switched to erlotinib. The median duration of EGFR-TKI therapy was 510 days (range: 122–1912 days; Table 1).

Table 1

Patient characteristics

Patient characteristics	(%)
Age (years)
Range	54–79
Gender
Male	5 (33.3)
Female	10 (76.7)
Smoking status
Non-smoker	9 (60.0)
Former Smoker	6 (40.0)
Stage
IV	14 (93.4)
rIVa	1 (6.6)
1st line	5 (33.3)
2nd line	7 (46.7)
3rd line	2 (13.4)
Subsequent therapy	1 (6.6)

arIV recurrent stage IV

EGFR sequence variations are listed in Table 2. All patients were diagnosed with adenocarcinomas harboring EGFR activating mutations (seven cases of exon 19 deletion, seven cases of L858R in exon 21, and one case of L861Q in exon 21). Of the 15 cases, acquired EGFR T790M resistance mutations in exon 20 were detected in 9 (60.0 %) patients. Of particular interest were cases 7, 8, and 10, in which T790M mutations were not detected by high-sensitivity conventional PCR-based methods, such as peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp [16], or Cycleave real-time PCR [15].

Table 2

Clinical characteristics and next-generation sequencing results

	Histology	EGFR Sequence Variants	Frequency (%)	Allele Call	Exon 20 T790M	Frequency (%)	Conversion to SCLC	Prior TKIs	Duration (days)
Case 1	Adenocarcinoma	Exon 19	44.3	Heterozygous	Yes	7.2	No	Erlotinib	681
		E746_T750 del
Case 2	Adenocarcinoma	Exon 19	59.4	Heterozygous	No	-	No	Gefitinib	537
		E746_T751 del > A
Case 3	Adenocarcinoma	Exon 21 L858R	46.1	Heterozygous	No	-	No	Gefitinib	195
		Exon 18 T725R	30.6	Heterozygous
Case 4	Adenocarcinoma	Exon 21 L858R	23.3	Heterozygous	No	-	No	Erlotinib	217
		Exon 20 S768I	10.0	Heterozygous
Case 5	Adenocarcinoma	Exon21 L858R	56.9	Heterozygous	No	-	No	Gefitinib	1105
		Exon 18 E709G	54.5	Heterozygous
Case 6	Adenocarcinoma	Exon 19	97.2	Homozygous	Yes	21.8	No	Erlotinib	693
		E746_T750 del
Case 7	Adenocarcinoma	Exon 21 L858R	13.8	Heterozygous	Yes	5.2	No	Erlotinib	537
Case 8	Squamous cell carcinoma	Exon 19	86.9	Heterozygous	Yes	7.3	No	Erlotinib	315
		E746_T750 del
Case 9	Adenocarcinoma	Exon 19	65.3	Heterozygous	Yes	41.3	No	Erlotinib	1555
		E746_T750 del
Case 10	Adenocarcinoma	Exon21 L858R	11.2	Heterozygous	Yes	4.8	No	Gefitinib	1912
Case 11	Adenocarcinoma	Exon 19	46.4	Heterozygous	Yes	11.0	No	Erlotinib	256
		E746_T750 del
Case 12	Adenocarcinoma	Exon21 L858R	22.2	Heterozygous	No	-	No	Erlotinib	924
		Exon 21 G873R	10.8	Heterozygous
Case 13	Adenocarcinoma	Exon 21 L861Q	59.9	Heterozygous	No	-	No	Gefitinib Erlotinib	1304122
		Exon 20 P772S	10.2	Heterozygous
		Exon19 L747S	11.8	Heterozygous
		Exon2 A289V	12.3	Heterozygous
Case 14	Adenocarcinoma	Exon 19	80.82	Heterozygous	Yes	14.8	No	Erlotinib	392
		E746_T750 del
Case 15	Adenocarcinoma	Exon21 L858R	76.7	Heterozygous	Yes	10.3	No	Erlotinib	339

In addition to T790M mutations, a large number of activating mutations were identified outside of EGFR. MET amplification, another common mutation associated with EGFR-TKI resistance, was not seen (Fig. 1), which is also confirmed by copy number analysis of NGS sequencing data (data not shown). Further screening of an additional 50 known oncogenes revealed a quite number of mutations in at least 32 genes (Table 3), including 13 cases (86.7 %) of TP53 P72R mutations, 5cases (33.3 %) of KDR Q472H, and 2 cases (13.3 %) of KIT M541L. A full list of genes analyzed in this study is shown in Table 4.

Fig. 1

Quantitaive polymerase chain reaction (qPCR) MET copy number gain (CNG) analysis for 15 cases

Table 3

Coexisting somatic mutations resulting in amino-acid changes identified using the Ion AmpliSeq Hotspot Panel version 2

		Frequency (%)		Frequency (%)		Frequency (%)		Frequency (%)		Frequency (%)
Case 1	KIT M541L (COSM 28026)	70.9	TP53 P72R	53.2	---	---	---	---	---	---
Case 2	PTEN L57W (COSM 5253)	21.2	---	---	---	---	---	---	---	---
Case 3	TP53 P72R	57.0	CTNNB1 D32N (COSM 5672)	34.5	TP53 V73 del	29.1	CDH1 Q346* (COSM 19524)	25.1	---	---
Case 4	TP53 P72R	60.3	TP53 R337C (COSM 11071)	18.0	---	---	---	---	---	---
Case 5	TP53 P72R	46.9	KDR Q472H	46.9	KIT G534C	46.3	APC S1463fs	42.5	---	---
Case 6	PDGFRA P567Q	100	TP53 V73W	72.6	TP53 P151S	57.5	KDR Q472H	42.4	ERBB4 C614Y	38.2
	SMAD4 R189H	29.0	PTEN R233Q	18.5	APC D1591N	18.4	HRAS T64*	17.9	AKT1 T21I	16.4
	KIT L647F	16.2	SKT11 D352N	15.1	PTEN H123Y (COSM 5078)	7.3	PTEN R130Q (COSM 5033)	7.2	---	---
Case 7	TP53 P72R	96.7	SKT11 F345L	53.5	SKT11 P281L	53.3	KDR Q472H	42.6	---	---
Case 8	TP53 P72R	98.4	KIT M541L (COSM 28026)	59.8	TP53 V154G (COSM 43903)	35.4	KDR Q472H	26.7	SMAD4 G423R	14.7
	ABL1 I347fs	11.1	ERBB4 C759T	8.8	FBXW7 M467I	8.0	MLH1 A169V	8.0	KDR G1284R	7.9
	APC P1433L	6.7	TP53 F338L	6.5	SMO P610S	6.4	MET D340A	5.8	NOTCH1 V1575M	5.7
	PTEN A328E	5.6	APC G1374K (COSM 18737)	5.1	MLH1 R148W	5.0	---	---	---	---
Case 9	APC E1464fs	59.2	TP53 P72R	48.2	BRAF G442D	6.1	MET G1102D	5.5	SMO T223I	5.0
Case 10	MET N375K	55.7	TP53 P72R	42.0	CTNNB1 G34V	6.5	---	---	---	---
Case 11	TP53 P72R	68.5	PTEN N329fs (COSM 4932)	39.5	TP53 K132R (COSM 11582)	29.7	---	---	---	---
Case 12	TP53 P72R	98.1	KDR Q472H	96.4	TP53 V272fs	21.0	RB1 I682T	12.6	APC P1433L	9.6
	RET E884V	9.1	SMAD4 V354L	8.0	---	---	---	---	---	---
Case 13	TP53 P72R	99.1	CDKN2 G155S	51.6	FLT3 W603*	45.2	KRAS E37K	33.3	SMO P641L	23.7
	IDH1 L103M	20.0	TP53 R267Q (COSM 43923)	18.8	GNA11 D205N	16.2	SMARCB1 P165S	14.0	RB1 M761T	13.9
	SMARCB1 V145L	12.4	TP53 G245R (COSM 10957)	10.8	NOTCH1 H1591T	10.7	ERBB4 G240V	10.0	KIT S715N	9.9
	FBXW7 R505H (COSM 25812)	9.8	FBXW7 M498I	9.2	MET S186L	8.8	IDH1 A111V	8.8	JAC3 V133I	8.5
	KIT V825I (COSM 19110)	8.1	TP53 G112S	6.5	TP53 K132E (COSM 10813)	6.3	HNF1A A193V	6.3	VHL K171T	5.7
	ALK P1191A	5.6	HNF1A T204I	5.3	---	---	---	---	---	---
Case 14	PTEN H1047L	62.9	FGFR3 R765S	7.2	IDH1 P118L	5.7	---	---	---	---
Case 15	TP53 P72R	100	MET A179M	5.1	---	---	---	---	---	---

Table 4

Target genes in the Ion AmpliSeq Hotspot Panel version 2

ABL1	EZH2	JAK3	PTEN
AKT1	FBXW7	IDH2	PTPN11
ALK	FGFR1	KDR	RB1
APC	FGFR2	KIT	RET
ATM	FGFR3	KRAS	SMAD4
BRAF	FLT3	MET	SMARCB1
CDH1	GNA11	MLH1	SMO
CDKN2A	GNAS	MPL	SRC
CSF1R	GNAQ	NOTCH1	STK11
CTNNB1	HNF1A	NPM1	TP53
EGFR	HRAS	NRAS	VHL
ERBB2	IDH1	PDGFRA
ERBB4	JAK2	PIK3CA

Discussion

In this study we analyzed biopsy specimens of patients who underwent second biopsy after treatment failure with the first generation EGFR-TKIs. There was a significant difference between the frequency of EGFR T790M and other EGFR-activating mutations, with significant variability among cases (4.8–41.3 %). The existence of EGFR and other mutations within the same tumor sample identified by NGS highlights the importance of this type of analysis in guiding appropriate cancer therapy.

High-throughput sequencing was able to detect T790M mutation in a number of cases with the same accuracy of conventional highly sensitive conventional PCR methods, such as PNA-LNA PCR clamp [16] and Cycleave real-time PCR [15]. While high sensitivity and specificity of these methods is well established [19-27], the use of NGS provides important advantages with clarifying activating mutation rate in tumor sample as well as greater detection of rare mutations outside of target areas [28-31]. In addition, to emphasize the power of NGS in clinical practice, we should also try to develop its applications and usages such as challenging specimens or testing processes, such as peripheral blood in the future.

NGS is also able to overcome issue of germ-line DNA contamination, similar to that of new PCR methods, such as digital PCR [32]. This tolerance of germ-line DNA contamination allows for more streamlined sample preparation techniques, without need for time-consuming procedures such as macro- or micro-dissection. In this study, all samples were extracted from FFPE biopsy specimens, highlighting both versatility and potential use of NGS in clinical settings. Furthermore NGS is able to quantify gene mutations within a tumor sample. Due to the unpredictablity of PCR amplification and germ line DNA contamination, observed mutations does not always reflect the penetrance of a mutation within a sample. While most highly sensitive detection methods provide only categorical results such as positive and negative, our analysis was able to identify the degree of EGFR T790M and other EGFR-activating mutations within a sample that could not be explained by germ-line DNA contamination and/or PCR efficacy. These results are consistent with previous reports detailing T790M allelic frequency in terms of both intra-tumor heterogeneity in localized lung adenocarcinomas [33] and allelic imbalances [34]. Our analysis was able to identify the degree of EGFR T790M and other EGFR-activating mutations within a sample that could not be explained by germ-line DNA contamination and/or PCR efficacy. Future treatment with next-generation EGFR-TKIs targeting T790M is likely to be informed by such analyses, as patients should be treated based upon their EGFR acquired mutation [35].

In addition to EGFR mutations, we also evaluated another 50 oncogenes thought to have an important role in cancer pathogenesis (Table 4). A large number of mutations were identified in this analysis. However, how much extent these genes affect tumorigenicity, tumor progression, and resistance to EGFR-TKIs is difficult to assess, as some mutations may represent only passive alterations (passenger mutations). Although many of these mutations were identified in a single patient, a series of mutations including TP53 P72R, KDR Q472R, and KIT M541L were detected in more than two cases, suggesting a role in disease progression.

TP53 P72R was the most common mutation, detected in 13 of 15 cases (86.7 %). In human populations, TP53 codon 72 is encoded by the nucleotide sequence CCC, which encodes proline, or CGC, which encodes arginine. While proline is the most common amino acid found at this residue, comparative sequence analyses have detected a high degree (>50 %) of TP53-R72 variants among certain populations [36]. The current understanding of TP53 biology is that TP53-R72 is more effective at inducing apoptosis and protecting stressed cells from neoplastic development than the more common TP53-P72 [37]. However, it is not yet understood how these functional differences might translate between in vitro and in vivo settings [38, 39], making it difficult to assess the role of this sequence variant of EGFR-TKI resistance.

KDR (kinase insert domain receptor, also known as VEGFR2) is an important factor in tumor development and progression due to its pro-angiogenic effects [40]. KDR Q472H mutations were detected in 5 of 15 cases (33.3 %), making it the second most common gene variant observed outside of EGFR. In human populations, codon 472 of KDR is encoded by the nucleotide sequence CAA, which encodes glutamine, or CAT, which encodes histidine. The Q472H variant is thought to affect protein function due to increased phosphorylation after vascular endothelial growth factor (VEGF)-A stimulation, along with increased binding efficiency for VEGF-A165 [41]. The effect of Q472H on microvessel density is thought to occur as a result of increased phosphorylation of VEGFR2 [42]. Here, increased microvessel density may have contributed to EGFR-TKI resistance, suggesting that VEGFR2 inhibition may inhibition may become an important therapeutic option in patients with documented EGFR-TKI resistance.

V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog (KIT) M541L substitutions were detected in 2 of 15 cases (13.3 %). c-KIT is one of the primary targets of imatinib, and mutations in KIT are predictive of the efficacy of the drug in gastrointestinal stromal tumors (GIST) [43]. Several case reports have suggested a potential role of the KIT M541L variant in the sensitivity of Imatinib for aggressive fibromatosis [44-46]. Furthermore, a wide array of in vitro analyses support a role for the L541 variant in tumorigenesis. FDC-P1 cells transfected with KIT-L541 showed an enhanced proliferative response, while KIT-L541 cells were more sensitive to imatinib than those expressing wild-type KIT [47]. Inokuchi, et al. observed a higher frequency of L541 variants among patients with chronic myelogenous leukemia (CML), which is consistent with increased tyrosine kinase activation and proliferative responses in KIT-L541 cells relative to wild-type controls [48]. From the view point of EGFR-TKI resistance, these data suggest a causative role for the KIT L541 variant in recurrence and drug resistance of NSCLC. Suppression of KIT with drugs like Imatinib may be a useful therapeutic choice in patients with KIT-variant tumors.

Five (cases 3, 4, 5, 12 and 13) out of six NSCLC patients that are negative for EGFR-T790M mutation harbored “compound mutations” (a rare EGFR mutation in combination with a more frequent activating mutation). On the other hand, all T790M-positive tumors (cases 1, 6, 7, 8, 9, 10 and 11) lack an additional rare mutation apart from the presence of a frequent inhibitor-sensitive EGFR mutation. Among these compound mutations (specifically rare mutations), tumors harboring S768I in exon 20 is known as resistant to EGFR-TKIs. On the contrary, tumors harboring point mutations in exon 18 and dual mutation of exon 19 deletion and S768I are reported to possible response to EGFR-TKIs. There have been limited data in other compounds mutations. So a role of these mutations in causing drug resistance in T790M-negative patients is uncertain and need to be evaluated [49].

This study has its limitations. The strongest limitations include a small sample size, and the retrospective nature of the study preventing the comparison of our findings to non-lesional or pre-treatment results. With this limitation of not having pre-treatment results, the role of activating mutations in additional oncogenes in TKI-resistance may be the primary cause for TKI resistance especially in the case of KDR Q472H mutations. A larger prospective study with strict enrollment criteria is definitely needed to overcome these limitations.

Conclusion

In conclusion, our study showed that NGS could be useful to detect EGFR T790M variants in patients not otherwise found with other conventional PCR based methods. Furthermore, our results highlight the difference of the extent of EGFR T790M and other EGFR-activating mutations among tumor samples, which may indicate the heterogeneity of acquired mutations. Identification of additional sequence variations in potential oncogenes that may affect EGFR-TKI resistance would suggest a series of new therapeutic agents targeting on a patient’s underlying genetic profile.